KNSA (Kiniksa Pharmaceuticals, Ltd.) Sof foyda

KNSA (Kiniksa) - kompaniyaning tovar belgisi

Kiniksa Pharmaceuticals (KNSA) o'sishi kamyob autoimmun patologiyalar uchun terapiyalarni ishlab chiqish va uning R&D portfelini diversifikatsiya qilishga asoslangan. Kompaniyaning sof foydasi ushbu muvaffaqiyatni aniq tasdiqlaydi, 0.11 ko'rsatkichi esa ushbu baholash parametrini tavsiflaydi. Monopoliya maqomi antitelolarning patent himoyasi bilan ta'minlangan, perikarditni davolash uchun yuqori talabga ega bo'lgan dori vositasi esa daromad generatori vazifasini o'taydi.

KNSA (Kiniksa Pharmaceuticals) Sof foyda tarixi 04.07.2022dan 31.10.2026gacha

Kiniksa (KNSA) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Kiniksa Corp|KNSA - Tahlilchilar konsensus prognozi
- biznesning bozor baholash ko'rsatkichlari:
Bozor kapitallashuvi Kiniksa Corp|KNSA - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Aksiyaning buxgalteriya qiymati Kiniksa|KNSA - Balans kapitallashuvi|Balans qiymatiga nisbatan bozor kapitallashuvi kiniksa.com|KNSA - Kompaniyaning jami aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Kiniksa Pharmaceuticals|KNSA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Kiniksa Pharmaceuticals, Ltd.|KNSA - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar Kiniksa Corp|KNSA - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi Kiniksa|Shoshilinch likvidlik kiniksa.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
KNSA - Kompaniyaning sof foydasi
Kompaniyaning jamlanma tahlili:Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Ltd asosiy tovari

Ushbu ko'rsatkich barcha operatsion va moliyaviy xarajatlar chegirib tashlanganidan keyingi sof naqd pul balansini aks ettirib, likvidlikning o'zgarishi sharoitida qiymat yaratishning haqiqiy samaradorligini namoyish etadi. Kiniksa Pharmaceuticals (KNSA) naqd foydasining tahlili biznesning barqarorligini baholash imkonini beradi, bunda Inertia dori vositasining sotuvidan olingan barqaror daromad o'sishi terapiyaning yuqori tijorat qiymatini tasdiqlaydi va kapitalning kamayishi risklarini minimallashtiradi.

Asosiy raqobatchilar

Sof daromad argenx BVBA|BNTX (BioNTech SE) - Sof foyda|Sof foyda Abivax Pharma|Sof daromad ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Yakuniy foyda|Sof foyda IMVT (Immunovant Corp)|Sof moliyaviy natija Grifols Biemat (GRFS)|ADPT - Kompaniyaning sof foydasi|celldex.com (CLDX) - Sof daromad|Aurinia Pharmaceuticals Inc. (AUPH) - Kompaniyaning sof foydasi|Sof daromad BioCryst Pharmaceuticals, Inc.|Sof daromad VERA|Sof foyda Dianthus Corp|Kompaniyaning sof foydasi Pharvaris N.V. (PHVS)|AbCellera Biologics Inc. - Kompaniya foydasi|Sof foyda TRML (Tourmaline Bio)|Precigen Inc (PGEN) - Kompaniyaning sof daromadi|PHAR - Kompaniyaning sof foydasi|NKTR - Sof foyda|UPB: Sof foyda|ZBIO - Sof moliyaviy natija|Kompaniyaning sof foydasi Immunome|Kompaniya foydasi GOSS (Gossamer Bio Inc)|Sof foyda KALV|Sof moliyaviy natija Septerna Pharma|Kompaniyaning sof foydasi Pieris Pharmaceuticals PVLA|Sof foyda savarapharma.com SVRA|RIGL - Kompaniyaning sof foydasi|Sof moliyaviy natija AnaptysBio Inc ANAB|ATXS: Sof foyda|enGene Corp (ENGN) - Sof foyda|Sof daromad RAPT|JBIO: Yakuniy foyda|Kompaniyaning sof foydasi Aclaris Therapeutics, Inc. (ACRS)|KYTX: Soliqdan keyingi foyda|Sof foyda TLSA (Tiziana Life Sciences PLC)|Yakuniy foyda CABA|Ventyx Biosciences - Sof foyda|THTX - Sof foyda|Avalo Therapeutics (AVTX) - Kompaniyaning sof foydasi|Eledon Pharmaceuticals Inc. - Yakuniy foyda|Kompaniyaning sof foydasi Agenus Inc|Sof daromad Climb Bio, Inc (CLYM)|Sof foyda ZURA|Sof foyda atyrpharma.com (ATYR)|Sof foyda ADAG (Adagene Inc.)|IMA - Sof daromad|Shattuck Therapeutics - Sof foyda|Kompaniyaning sof daromadi Equillium, Inc.|CNTB (connectbiopharm.com) - Sof daromad|Immunic (IMUX) - Sof foyda|Sof daromad ATRA|IFRX (InflaRx GmbH) - Soliqlar to‘langandan keyingi foyda|Sof foyda XFOR|Sof moliyaviy natija adicetbio.com|Sof foyda CELU (Celularity)|INMB - Sof daromad|Barinthus Biotherapeutics plc - Sof foyda|KZR - Sof foyda|SAB Biotherapeutics, Inc (SABS) - Kompaniyaning sof foydasi|AKTX (Akari Therapeutics, Plc) - Kompaniyaning sof foydasi|Kompaniyaning sof foydasi Enlivex Therapeutics Ltd|Q32 Bio Corp (QTTB) - Sof moliyaviy natija|Kompaniyaning sof foydasi GeoVax (GOVX)|Sof foyda Edesa Biotech Inc (EDSA)|Kompaniyaning sof foydasi iBio Corp IBIO|CARM: Kompaniya foydasi|XTLB - Kompaniyaning sof foydasi|Sof moliyaviy natija Bolt Biotherapeutics BOLT|HCWB: Sof foyda|Aptevo Therapeutics Inc. (APVO) - Sof foyda|Kompaniyaning sof foydasi AIM ImmunoTech|Aditxt Corp - Soliqdan keyingi foyda|Sof foyda GRI|XRTX (xortx.com) - Yakuniy foyda|Sof foyda HIND (Vyome Holdings)|Sof foyda Revelation Biosciences Inc REVB|INDP - Kompaniyaning sof foydasi|Yakuniy foyda SCNI (BiondVax Pharmaceuticals)|calcimedica.com (CALI) - Kompaniyaning sof foydasi|Sof daromad Affimed N.V.|ALLK (Allakos Inc) - Sof foyda|Sof foyda HOOKIPA|Sof daromad IGMS (IGM Biosciences, Inc.)|ITOS (iTeos Pharma) - Yakuniy foyda|Sof foyda OCEA (Ocean Biomedical, Inc.)|Sof moliyaviy natija tcbiopharm.com (TCBP)|THRD - Kompaniyaning sof foydasi